Systemic mastocytosis

被引：188

作者：

Akin, C ^{[1
]}

Metcalfe, DD ^{[1
]}

机构：

[1] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA

来源：

ANNUAL REVIEW OF MEDICINE | 2004年 / 55卷

关键词：

mast cells; urticaria pigmentosa; c-kit; bone marrow;

D O I：

10.1146/annurev.med.55.091902.103822

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 [基础医学];

摘要：

Systemic mastocytosis is a clonal disorder of the mast cell and its progenitor. The symptoms of systemic mastocytosis are due to the pathologic accumulation and activation of mast cells in various tissues such as bone marrow, skin, gastrointestinal tract, liver, and spleen. Recent studies revealed striking differences between the molecular and cellular biology of mast cells in patients with mastocytosis and those of healthy individuals. These findings are being used in formulating diagnostic criteria as well as designing novel treatment approaches to the disease.

引用

收藏

页码：419 / 432

页数：14

相关论文

共 57 条

[1]

Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis [J].

Akin, C ;

Kirshenbaum, AS ;

Semere, T ;

Worobec, AS ;

Scott, LM ;

Metcalfe, DD .

EXPERIMENTAL HEMATOLOGY, 2000, 28 (02) :140-147

[2]

Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology [J].

Akin, C ;

Schwartz, LB ;

Kitoh, T ;

Obayashi, H ;

Worobec, AS ;

Scott, LM ;

Metcalfe, DD .

BLOOD, 2000, 96 (04) :1267-1273

[3]

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit [J].

Akin, C ;

Brockow, K ;

D'Ambrosio, C ;

Kirshenbaum, AS ;

Ma, YS ;

Longley, BJ ;

Metcalfe, DD .

EXPERIMENTAL HEMATOLOGY, 2003, 31 (08) :686-692

[4]

An immunohistochemical study of the bone marrow lesions of systemic mastocytosis - Expression of stem cell factor by lesional mast cells [J].

Akin, C ;

Jaffe, ES ;

Raffeld, M ;

Kirshenbaum, AS ;

Daley, T ;

Noel, P ;

Metcalfe, DD .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2002, 118 (02) :242-247

[5]

Slowly progressive systemic mastocytosis with high mast-cell burden and no evidence of a non-mast-cell hematologic disorder: an example of a smoldering case? [J].

Akin, C ;

Scott, LM ;

Metcalfe, DD .

LEUKEMIA RESEARCH, 2001, 25 (07) :635-638

[6]

[Anonymous], 1869, Br Med J, V2, P323

[7]

Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: Relationship to symptomatology, tryptase levels, and bone marrow pathology [J].

Brockow, K ;

Akin, C ;

Huber, M ;

Metcalfe, DD .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 48 (04) :508-516

[8]

Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: Correlation with dermal mast-cell numbers and mast-cell tryptase [J].

Brockow, K ;

Akin, C ;

Huber, M ;

Scott, LM ;

Schwartz, LB ;

Metcalfe, DD .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) :82-88

[9]

Buchdunger E, 1996, CANCER RES, V56, P100

[10]

Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139

← 1 2 3 4 5 6 →